Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-22T23:19:08.529Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone-induced acute pancreatitis

Published online by Cambridge University Press:  19 January 2007

Martin Holtmann ,
Fabian Härtling  and
Fritz Poustka
Martin Holtmann
Affiliation:
Department of Child and Adolescent Psychiatry and Psychotherapy, Goethe-University of Frankfurt/Main, Frankfurt, Germany
Fabian Härtling
Affiliation:
Department of Child and Adolescent Psychiatry and Psychotherapy, Goethe-University of Frankfurt/Main, Frankfurt, Germany
Fritz Poustka
Affiliation:
Department of Child and Adolescent Psychiatry and Psychotherapy, Goethe-University of Frankfurt/Main, Frankfurt, Germany
Get access

Abstract

We report on an adolescent with Asperger's syndrome who developed acute pancreatitis during treatment with risperidone and citalopram. On discontinuation of psychopharmacotherapy, he fully recovered. A rechallenge testing of citalopram did not result in a relapse of pancreatitis. Other known causes of pancreatitis were not obvious. Clinicians should be alert to this rare adverse event in patients who exhibit symptoms of an acute abdominal disorder during risperidone treatment.

Keywords

Risperidonepancreatitisside effectadolescence
Type
Case Report
Information
Journal of Psychiatric Intensive Care , Volume 2 , Issue 1 , June 2006 , pp. 39 - 41
Copyright
© 2006 NAPICU

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Berent, I., Carabeth, J., Cordero, M.M., et al. (1997) Pancreatitis associated with risperidone treatment? Am J Psychiatry 154: 130–131.Google Scholar
Cordeiro, Q. Jr., and Elkis, H. (2001) Pancreatitis and cholestatic hepatitis induced by risperidone. J Clin Psychopharmacol 21: 529–530.Google Scholar
Gagliano, A., Germano, E., Pustorino, G., et al. (2004) Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14: 39–47.Google Scholar
Hanft, A. and Bourgeois, J. (2004) Risperidone and pancreatitis. J Am Acad Child Adolesc Psychiatry 43: 1458–1459.Google Scholar
Holtmann, M., Kopf, D., Mayer, M., et al. (2003) Risperidone-associated steatohepatitis and excessive weight-gain. Pharmacopsychiatry 36: 206–207.Google Scholar
Kohnke, M.D., Griese, E.U., Stosser, D., et al. (2002) Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35: 116–118.Google Scholar
Koller, E.A., Cross, J.T., Doraiswamy, P.M., et al. (2003) Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 23: 1123–1130.Google Scholar
Malone, R.P., Maislin, G., Choudhury, M.S., et al. (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41: 140–147.Google Scholar
Spigset, O., Hagg, S., Bate, A. (2003) Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 18: 157–161.Google Scholar